Top Story Today
Novartis Bet $7.8 Billion That Your Body Can Build Its Own Drug Factory
Novartis paid $575 million upfront (up to $7.8 billion total) to license an mRNA therapy from China's Abogen Biosciences that turns your own cells into medicine-producing factories. The drug, ABO2203, delivers mRNA instructions wrapped in tiny fat bubbles so your cells manufacture a T-cell engager protein that wipes out rogue B cells in autoimmune disease. Unlike CAR-T therapy, which requires weeks of lab engineering, this is a single injection with a transient effect. Preclinical data showed complete B-cell depletion with a gentler safety profile than traditional protein versions.
Why it matters: One of the largest China-originated biotech deals ever signals that big pharma sees in-vivo mRNA immune therapies, not traditional CAR-T, as the most scalable path to resetting the immune system in autoimmune disease.
Read more →Deals and M&A
Novartis Spends Up to $3.2 Billion on a Technology That Turns IV Drips Into Quick Shots
Days after the Abogen deal, Novartis signed another blockbuster: up to $3.2 billion for South Korean biotech Alteogen's enzyme platform that converts IV biologics into subcutaneous injections. The tech lets patients swap hours at an infusion center for a quick shot at home. Analysts flagged the deal as a direct threat to Halozyme, the longtime king of subcutaneous reformulation.
Read more →Fresenius Kabi Pays Up to 750 Million Euros to Fully Own Its Biosimilar Factory
Fresenius Kabi spent up to 750 million euros to buy the 45% of biosimilar maker mAbxience it didn't already own. The timing isn't subtle: blockbuster biologics like Keytruda face patent expiration by 2028, and the biosimilar market could hit $193 billion by 2035. Full ownership means faster decisions in a race where manufacturing speed wins.
Read more →Three Pharma Giants Team Up for a Cancer Combination Trial Nobody Expected
Daiichi Sankyo, AstraZeneca, and Summit Therapeutics are launching a Phase 3 trial pairing a TROP2 antibody-drug conjugate with a PD-1/VEGF bispecific antibody in triple-negative breast cancer. The rare three-company collaboration follows AstraZeneca's $2 billion equity bet on Summit and could set the template for how next-generation oncology combinations get built.
Read more →Clinical Wins and Regulatory Moves
Amgen's $28 Billion Horizon Bet Just Got Its Best News Yet
A drug inherited from the $27.8 billion Horizon acquisition just hit its primary endpoint in Sjogren's disease, a condition with zero FDA-approved treatments. Dazodalibep showed statistically significant improvement in systemic disease activity over 48 weeks, with benefits starting as early as week four. A second pivotal trial reads out later this year.
Read more →Regeneron Found a Way to Give Back the Muscle Wegovy Takes Away
Phase 2 data showed Regeneron's trevogrumab cut semaglutide-related muscle loss roughly in half, and patients who stopped Wegovy but continued the antibody saw muscle mass climb back to baseline. The catch: a triple-combo arm saw two patient deaths and high discontinuation rates, shelving that approach for now.
Read more →First-Ever Pediatric Drug Approved for Obstructive Hypertrophic Cardiomyopathy
The FDA approved Bristol Myers Squibb's Camzyos for adolescents aged 12 to 17, making it the first drug ever greenlit for pediatric obstructive HCM. In the pivotal trial, heart obstruction dropped by 48 mm Hg more than placebo (a massive difference), with no patients experiencing dangerously low heart function.
Read more →Wave Life Sciences Gets FDA Support for a One-Trial Path to Approval
The FDA backed Wave's plan to seek approval for its RNA-editing therapy in alpha-1 antitrypsin deficiency using a single registrational trial with a built-in interim analysis. Early data showed patients producing functional protein from essentially zero at baseline, with functional M-AAT making up more than 60% of total AAT. If it works, the approach could set a precedent for the entire RNA-editing drug class.
Read more →The Harsh Side of Biotech
Lilly Walked Away, and 40% of Foghorn's Staff Paid the Price
Eli Lilly ended its partnership with Foghorn Therapeutics after disappointing Phase 1 data for cancer drug FHD-909, and the fallout was swift: 40% of staff cut, stock down sharply intraday. The collapse killed a deal once worth up to $1.6 billion and left Foghorn scrambling to survive on early-stage programs alone.
Read more →Adecto Shuts Down After Years of Science and Zero Venture Dollars
Adecto Pharmaceuticals ceased operations after its grant-funded model couldn't bridge the gap to venture capital. The company researched a cancer target called ADAM8 but never attracted private investment. Its IP returns to the founders, joining a growing list of orphaned biotech assets in a market where early-stage funding has collapsed to its lowest level in years.
Read more →